Portal de Periódicos da CAPES

Pharmacokinetics and Safety of Indinavir in Human Immunodeficiency Virus-Infected Pregnant Women

2006; American Society for Microbiology; Volume: 51; Issue: 2 Linguagem: Inglês

10.1128/aac.00420-06

1098-6596

Jashvant D. Unadkat, Diane W. Wara, Michael D. Hughes, Anita Mathias, Diane T. Holland, Mary E. Paul, James D. Connor, Sharon Huang, Bach-Yen Nguyen, D. Heather Watts, Lynne Mofenson, Elizabeth Smith, Paul Deutsch, Kathleen A. Kaiser, Ruth Tuomala,

HIV/AIDS Research and Interventions

ABSTRACT Human immunodeficiency virus-infected women ( n = 16) received indinavir (800 mg three times a day) plus zidovudine plus lamivudine from 14 to 28 weeks of gestation to 12 weeks postpartum. Two women and eight infants experienced grade 3 or 4 toxicities that were possibly treatment related. Indinavir area under the plasma concentration-time curve was 68% lower antepartum versus postpartum, suggesting increased intestinal and/or hepatic CYP3A activity during pregnancy.